Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2010 1
2011 1
2012 1
2013 1
2014 2
2016 1
2019 1
2020 6
2021 5
2022 4
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Citations

6 articles found by citation matching
Show all

Search results

Filters applied: . Clear all
Page 1
Cilostazol for secondary stroke prevention: systematic review and meta-analysis.
Tan CH, Wu AG, Sia CH, Leow AS, Chan BP, Sharma VK, Yeo LL, Tan BY. Tan CH, et al. Stroke Vasc Neurol. 2021 Sep;6(3):410-423. doi: 10.1136/svn-2020-000737. Epub 2021 Feb 4. Stroke Vasc Neurol. 2021. PMID: 33542092 Free PMC article.
We aim to determine the efficacy and safety of cilostazol for secondary stroke prevention. METHODS: MEDLINE, EMBASE, Cochrane Library, Web of Science and ClinicalTrials.gov were searched from inception to 25 September 2020, for randomised trials compar …
We aim to determine the efficacy and safety of cilostazol for secondary stroke prevention. METHODS: MEDLINE, EMB …
Contemporary antiplatelet therapy for secondary stroke prevention: a narrative review of current literature and guidelines.
Shah J, Liu S, Yu W. Shah J, et al. Stroke Vasc Neurol. 2022 Oct;7(5):406-414. doi: 10.1136/svn-2021-001166. Epub 2022 Apr 7. Stroke Vasc Neurol. 2022. PMID: 35393359 Free PMC article.
Landmark studies and randomised controlled trials evaluating antiplatelet therapy for secondary stroke prevention are reviewed. Results from Cochrane systematic review, pooled data analysis and meta-analysis are discussed.Single-an …
Landmark studies and randomised controlled trials evaluating antiplatelet therapy for secondary stroke prevention are r …
Cilostazol Versus Aspirin for Secondary Stroke Prevention: Systematic Review and Meta-Analysis.
Lin MP, Meschia JF, Gopal N, Barrett KM, Ross OA, Ertekin-Taner N, Brott TG. Lin MP, et al. J Stroke Cerebrovasc Dis. 2021 Mar;30(3):105581. doi: 10.1016/j.jstrokecerebrovasdis.2020.105581. Epub 2020 Dec 31. J Stroke Cerebrovasc Dis. 2021. PMID: 33388632
We aimed to conduct a systematic review and meta-analysis to estimate the efficacy and safety of cilostazol compared to aspirin for stroke prevention in patients with previous stroke or transient ischemic attack (TIA). ...CO …
We aimed to conduct a systematic review and meta-analysis to estimate the efficacy and safety of cilostazol …
Cilostazol for Secondary Prevention of Stroke and Cognitive Decline: Systematic Review and Meta-Analysis.
McHutchison C, Blair GW, Appleton JP, Chappell FM, Doubal F, Bath PM, Wardlaw JM. McHutchison C, et al. Stroke. 2020 Aug;51(8):2374-2385. doi: 10.1161/STROKEAHA.120.029454. Epub 2020 Jul 10. Stroke. 2020. PMID: 32646330 Free PMC article.
In addition to weak antiplatelet effects, it stabilizes endothelium, aids myelin repair and astrocyte-neuron energy transfer in laboratory models, effects that may be beneficial in preventing small vessel disease progression. METHODS: A systematic review and …
In addition to weak antiplatelet effects, it stabilizes endothelium, aids myelin repair and astrocyte-neuron energy transfer in laboratory m …
Antiplatelet therapy for secondary prevention of lacunar stroke: a systematic review and network meta-analysis.
Hou X, Cen K, Cui Y, Zhang Y, Feng X. Hou X, et al. Eur J Clin Pharmacol. 2023 Jan;79(1):63-70. doi: 10.1007/s00228-022-03413-z. Epub 2022 Nov 7. Eur J Clin Pharmacol. 2023. PMID: 36342528
Funnel-plot symmetry was used to evaluate publication bias. The meta-analysis was performed by using STATA 16.0. RESULTS: Thirteen studies with a total of 33,011 subjects were included in this network meta-analysis. ...No significant inconsistency or p …
Funnel-plot symmetry was used to evaluate publication bias. The meta-analysis was performed by using STATA 16.0. RESULTS: Thir …
The Efficacy and Safety of Cilostazol vs. Aspirin for Secondary Stroke Prevention: A Systematic Review and Meta-Analysis.
Chai E, Chen J, Li C, Zhang X, Fan Z, Yang S, Zhao K, Li W, Xiao Z, Zhang Y, Tang F. Chai E, et al. Front Neurol. 2022 Feb 15;13:814654. doi: 10.3389/fneur.2022.814654. eCollection 2022. Front Neurol. 2022. PMID: 35242099 Free PMC article.
BACKGROUND: Cilostazol is often used in Asia-Pacific countries for stroke prevention. The current systematic review and meta-analysis aimed to evaluate the effectiveness, safety, and adverse outcomes of cilostazol monotherap …
BACKGROUND: Cilostazol is often used in Asia-Pacific countries for stroke prevention. The current systematic …
Antiplatelet drugs for secondary prevention in patients with ischemic stroke or transient ischemic attack: a systematic review and network meta-analysis.
Del Giovane C, Boncoraglio GB, Bertù L, Banzi R, Tramacere I. Del Giovane C, et al. BMC Neurol. 2021 Aug 16;21(1):319. doi: 10.1186/s12883-021-02341-2. BMC Neurol. 2021. PMID: 34399713 Free PMC article.
Within this network meta-analysis we aimed to summarize the current evidence for using antiplatelet drugs for secondary stroke prevention. ...SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42020159896 ....
Within this network meta-analysis we aimed to summarize the current evidence for using antiplatelet drugs for secondary …
Meta-analysis of cilostazol versus aspirin for the secondary prevention of stroke.
Dinicolantonio JJ, Lavie CJ, Fares H, Menezes AR, O'Keefe JH, Bangalore S, Messerli FH. Dinicolantonio JJ, et al. Am J Cardiol. 2013 Oct 15;112(8):1230-4. doi: 10.1016/j.amjcard.2013.05.067. Epub 2013 Jul 2. Am J Cardiol. 2013. PMID: 23827403 Review.
Aspirin is the most widely prescribed antiplatelet agent for the secondary prevention of stroke. Cilostazol, an antiplatelet and vasodilating agent, has shown promise for the secondary prevention of stroke. A systematic r …
Aspirin is the most widely prescribed antiplatelet agent for the secondary prevention of stroke. Cilostazol, an …
Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome.
Bala MM, Celinska-Lowenhoff M, Szot W, Padjas A, Kaczmarczyk M, Swierz MJ, Undas A. Bala MM, et al. Cochrane Database Syst Rev. 2020 Oct 12;10(10):CD012169. doi: 10.1002/14651858.CD012169.pub3. Cochrane Database Syst Rev. 2020. PMID: 33045766 Free PMC article.
OBJECTIVES: To assess the effects of antiplatelet (AP) or anticoagulant agents, or both, for the secondary prevention of recurrent thrombosis, particularly ischemic stroke, in people with APS. ...This study reported on stroke (very low-certainty eviden …
OBJECTIVES: To assess the effects of antiplatelet (AP) or anticoagulant agents, or both, for the secondary prevention of recur …
The efficacy and safety of cilostazol for the secondary prevention of ischemic stroke in acute and chronic phases in Asian population--an updated meta-analysis.
Shi L, Pu J, Xu L, Malaguit J, Zhang J, Chen S. Shi L, et al. BMC Neurol. 2014 Dec 20;14:251. doi: 10.1186/s12883-014-0251-7. BMC Neurol. 2014. PMID: 25527141 Free PMC article. Review.
BACKGROUNDS: While previous meta-analysis have investigated the efficacy of cilostazol in the secondary prevention of ischemic stroke, they were criticized for their methodology, which confused the acute and chronic phases of stroke …
BACKGROUNDS: While previous meta-analysis have investigated the efficacy of cilostazol in the secondary preve …
25 results